To determine if this mutual exclusivity applied to a larger sample size, we examined TERT alterations identified by us and others [40,42,45] together, as summarized in Figure 4B. Of the 347 HBV–HCC patients, 174 (50%) were found to have detectable TERT alterations. This evidence concerns the gene TERT and hepatocellular carcinoma.